Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,697 | $6,414 | $6,395 | $6,480 |
| - Cash | $560 | $392 | $445 | $446 |
| + Debt | $857 | $743 | $618 | $210 |
| Enterprise Value | $7,994 | $6,765 | $6,568 | $6,243 |
| Revenue | $364 | $267 | $51 | $8 |
| % Growth | 36.3% | 421.2% | 557.9% | – |
| Gross Profit | $319 | $222 | $39 | $4 |
| % Margin | 87.8% | 83.4% | 76.3% | 54.7% |
| EBITDA | -$290 | -$411 | -$529 | -$365 |
| % Margin | -79.8% | -154.2% | -1,034.1% | -4,688.1% |
| Net Income | -$378 | -$481 | -$583 | -$384 |
| % Margin | -104% | -180.5% | -1,139.6% | -4,931.6% |
| EPS Diluted | -6.53 | -8.55 | -10.4 | -7 |
| % Growth | 23.6% | 17.8% | -48.6% | – |
| Operating Cash Flow | -$306 | -$467 | -$496 | -$418 |
| Capital Expenditures | -$1 | -$2 | -$14 | -$24 |
| Free Cash Flow | -$308 | -$470 | -$510 | -$442 |